Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00985127 | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout | PHASE2 | COMPLETED | 99 | — | — | Sep 1, 2009 | Sep 1, 2010 | Jan 23, 2012 | 24 | United States |
| Arm | Type | Description |
|---|---|---|
| 40 mg | EXPERIMENTAL | 40 mg BCX4208 |
| 80 mg | EXPERIMENTAL | BCX4208 |
| 120 mg | EXPERIMENTAL | BCX4208 |
| sugar pill | PLACEBO_COMPARATOR | - |
| 160mg | EXPERIMENTAL | BCX4208 |
| 240mg | EXPERIMENTAL | BCX4208 |
| 320mg | EXPERIMENTAL | BCX4208 |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | administered daily for 21 days |
| BCX4208 | DRUG | Administered daily for 21 days. |
Inclusion Criteria: 1. Age ≥18 to \<70 years 2. Have read and signed the ICF after the nature of the study has been fully explained 3. Screening sUA ≥8.0 mg/dL 4. Diagnosis of gout according to the preliminary criteria of the American Rheumatism Association (1977) 5. Female participants must meet a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| Protalix | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |